0
Late-Breaking Abstracts |

Indacaterol/Glycopyrronium Reduces Moderate or Severe Exacerbations Compared With Salmeterol/Fluticasone, Irrespective of Number of Exacerbations in Previous Year: Indirect Comparison From FLAME and LANTERN Studies

Anthony Yadao, MD; Robert Fogel, MD; Tim Ayers, MD; Chau Thach, PhD; Francesco Patalano, MD; Donald Banerji, MD
Author and Funding Information

Novartis Pharmaceuticals Corporation, East Hanover, NJ


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):1317A. doi:10.1016/j.chest.2016.08.1448
Text Size: A A A
Published online

Extract

SESSION TITLE: Late-Breaking Abstracts

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 25, 2016 at 08:45 AM - 10:00 AM

PURPOSE: Acute exacerbations, marked by a rapid decline in lung function and poor patient-reported outcomes, are a cause of considerable morbidity and mortality associated with COPD, and incur significant healthcare utilization and associated costs. Here, we report the reduction in moderate or severe exacerbations with indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in COPD patients with ≥1 and 0-1 exacerbations in the previous year, from the FLAME and LANTERN studies, respectively.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543